Selective internal radiation therapy

Last updated
Selective internal radiation therapy
Radioembolisation.tif
Interventional radiologists performing radioembolisation
Other namestransarterial radioembolization (TARE)
Specialty oncology

Selective internal radiation therapy (SIRT), also known as transarterial radioembolization (TARE), radioembolization or intra-arterial microbrachytherapy is a form of radiation therapy used in interventional radiology to treat cancer. It is generally for selected patients with surgically unresectable cancers, especially hepatocellular carcinoma or metastasis to the liver. The treatment involves injecting tiny microspheres of radioactive material into the arteries that supply the tumor, where the spheres lodge in the small vessels of the tumor. Because this treatment combines radiotherapy with embolization, it is also called radioembolization. The chemotherapeutic analogue (combining chemotherapy with embolization) is called chemoembolization, of which transcatheter arterial chemoembolization (TACE) is the usual form.

Contents

Principles

Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators in radiation oncology; however, when irradiating using external beam radiotherapy, the beam will always need to travel through healthy tissue, and the normal liver tissue is very sensitive to radiation. [1] The radiation sensitivity of the liver parenchyma limits the radiation dose that can be delivered via external beam radiotherapy. SIRT, on the other hand, involves the direct insertion of radioactive microspheres to a region, resulting in a local and targeted deposition of radioactive dose. It is therefore well-suited for treatment of liver tumors. Due to the local deposition, SIRT is regarded as a type of locoregional therapy (LRT).[ citation needed ]

The liver has a dual blood supply system; it receives blood from both the hepatic artery and the portal vein. The healthy liver tissue is mainly perfused by the portal vein, while most liver malignancies derive their blood supply from the hepatic artery. Therefore, locoregional therapies such as transarterial chemoembolization or radioembolization, can selectively be administered in the arteries that are supplying the tumors and will preferentially lead to deposition of the particles in the tumor, while sparing the healthy liver tissue from harmful side effects. [2]

In addition, malignancies (including primary and many metastatic liver cancers) are often hypervascular; tumor blood supplies are increased compared to those of normal tissue, further leading to preferential deposition of particles in the tumors.[ citation needed ]

SIRT can be performed using several techniques, including whole liver treatment, lobar or segmental approaches. Whole liver SIRT targets the entire liver in one treatment and can be used when the disease is spread throughout the liver. Radiation lobectomy targets one of the two liver lobes and can be a good treatment option when only a single lobe is involved or when treating the whole liver in two separate treatments, one lobe at the time. The segmental approach, also called radiation segmentectomy, is a technique where a high dose of radiation is delivered in one or two Couinaud liver segments only. The high dose results in eradication of the tumor while damage to healthy liver tissue is contained to the targeted segments only. This approach results in effective necrosis of the targeted segments. Segmentectomy is only feasible when the tumor(s) are contained in one or two segments. Which technique is applied is determined by catheter placement. The more distally the catheter is placed, the more localized the technique. [3]

Therapeutic applications

Candidates for radioembolization include patients with:

1) Unresectable liver cancer of primary or secondary origin, such as hepatocellular carcinoma [4] and liver-metastases from a different origin (e.g. colorectal cancer, [5] breast cancer, [6] neuroendocrine cancer, [7] cholangiocarcinoma [8] or soft tissue sarcomas [9] )
2) No response or intolerance to regional or systemic chemotherapy
3) No eligibility for potentially curative options such as radiofrequency ablation. [10]

SIRT is currently considered as a salvage therapy. It has been shown to be safe and effective in patients for whom surgery is not possible, and chemotherapy was not effective. [4] [5] [11] [7] [8] Subsequently, several large phase III trials have been started to evaluate the efficacy of SIRT when used earlier in the treatment scheme or in combination treatments with systemic therapy.

SIRT, when added to first line therapy for patients with metastases of colorectal cancer, was evaluated in the SIRFLOX, [12] FOXFIRE [13] and FOXFIRE Global [14] studies. For primary liver cancer (HCC), two large trials comparing SIRT with standard of care chemotherapy, Sorafenib, have been completed, namely the SARAH [15] and SIRveNIB [16] trials.

Results of these studies, published in 2017 and 2018, reported no superiority of SIRT over chemotherapy in terms of overall survival (SARAH, [17] SIRveNIB, [18] FOXFIRE [19] ). In the SIRFLOX study, better progression-free survival was also not observed. [20] These trials did not give direct evidence supporting SIRT as a first-line treatment regime for liver cancer. However, these studies did show that SIRT is generally better tolerated than systemic therapy, with less severe adverse events. Simultaneously, for HCC, data derived from a large retrospective analysis showed promising results for SIRT as an earlier stage treatment, particularly with high dose radiation segmentectomy and lobectomy. [21]

More studies and cohort analyses are underway to evaluate subgroups of patients who benefit from SIRT as a first-line or later treatment, or to evaluate the effect of SIRT in combination with chemotherapy (EPOCH, [22] SIR-STEP, [23] SORAMIC, [24] STOP HCC [25] ).

For HCC patients currently ineligible for liver transplant, SIRT can sometimes be used to decreases tumor size allowing patients to be candidates for curative treatment. This is sometimes called bridging therapy. [26]

When comparing SIRT with transarterial chemoembolization (TACE), several studies have shown favorable results for SIRT, such as longer time to progression, [27] higher complete response rates and longer progression-free survival. [28]

Radionuclides and microspheres

There are currently three types of commercially available microsphere for SIRT. Two of these use the radionuclide yttrium-90 (90Y) and are made of either glass (TheraSphere) or resin (SIR-Spheres). The third type uses holmium-166 (166Ho) and is made of poly(l-lactic acid), PLLA, (QuiremSpheres). The therapeutic effect of all three types is based on local deposition of radiation dose by high-energy beta particles. All three types of microsphere are permanent implants and stay in the tissue even after radioactivity has decayed.

90Y, a pure beta emitter, has half-life 2.6 days, or 64.1 hours. 166Ho emits both beta and gamma rays emitter, with half-life 26.8 hours. Both 90Y and 166Ho have mean tissue penetration of a few millimeters. 90Y can be imaged using bremsstrahlung SPECT and positron emission tomography (PET). Bremsstrahlung SPECT uses of the approximately 23000 Bremsstrahlung photons per megabecquerel that are produced by interaction of beta particles with tissue. The positrons needed for PET imaging come from a small branch of the decay chain (branching ratio 32×10−6) that gives positrons. [29] 90Y's low bremsstrahlung photon and positron yield make it difficult to perform quantitative imaging. [30]

166Ho's additional gamma emission (81 KeV, 6.7%) makes 166Ho microspheres quantifiable using a gamma camera. Holmium is also paramagnetic, enabling visibility and quantifiability in MRI even after the radioactivity has decayed. [31]

Trade nameSIR-SpheresTheraSphereQuiremSpheres
Manufacturer Sirtex Medical Boston Scientific Quirem Medical (Terumo)
Mean diameter (μm)32 [32] 25 [32] 30 [33]
Specific gravity (g/dL) (compared to blood)1.6 (150%) [34] 3.6 (300%) [34] 1.4 (130%) [35]
Activity per particle (Bq)40-70 [32] 1250-2500 [36] 330-450 [33]
Microspheres per 3 GBq vial (millions)40-80 [34] 1.2 [34] 40-80 [37]
MaterialResin with bound yttriumGlass with yttrium in matrixPLLA with holmium
Radionuclide (half-life)90Y (64.1 hours)90Y (64.1 hours)166Ho (26.8 hours)
Beta-radiation (MeV) (Emax)2.28 [38] 2.281.77 (48.7%) [39]

1.85 (50.0%)

Gamma-radiation (keV)--81 (6.7%)

Regulatory approval

United States

Theraspheres (glass 90Y microspheres) are FDA approved under a humanitarian device exemption for hepatocellular carcinoma (HCC). SIR-spheres (resin 90Y microspheres) are FDA approved under premarket approval for colorectal metastases in combination with chemotherapy. [40]

Europe

SIR-Spheres were CE-marked as a medical device in 2002, for treating advanced inoperable liver tumors, and Theraspheres in 2014, for treating hepatic neoplasia. [37] QuiremSpheres (PLLA 166Ho microspheres) received their CE mark in April 2015 for treating unresectable liver tumors and are currently only available for the European market. [37] [41]

Procedure

90Y microsphere treatment requires patient-individualized planning with cross-sectional imaging and arteriograms. [42] Contrast computed tomography and/or contrast-enhanced magnetic resonance imaging of the liver is required to assess tumor and normal liver volumes, portal vein status, and extrahepatic tumor burden. Liver and kidney function tests should be performed; patients with irreversibly elevated serum bilirubin, AST and ALT are excluded, as these are markers of poor liver function. [43] Use of iodinated contrast should be avoided or minimized in patients with chronic kidney disease. Tumor marker levels are also evaluated. Hepatic artery technetium (99mTc) macro aggregated albumin (MAA) scan is performed to evaluate hepatopulmonary shunting (resulting from hepatopulmonary syndrome). Therapeutic radioactive particles travelling through such a shunt can result in a high absorbed radiation dose to the lungs, possibly resulting in radiation pneumonitis. Lung dose >30 gray means increased risk of such pneumonitis. [44]

Initial angiographic evaluation can include an abdominal aortogram, Superior mesenteric and Celiac arteriograms, and selective right and left liver arteriograms. These tests can show gastrointestinal vascular anatomy and flow characteristics. Extrahepatic vessels found on angiographic evaluation can be embolized, to prevent nontarget deposition of microspheres, that can lead to gastrointestinal ulcers. Or the catheter tip can be moved more distally, past the extrahepatic vessels. [45] Once the branch of the hepatic artery supplying the tumor is identified and the tip of the catheter is selectively placed within the artery, the 90Y or 166Ho microspheres are infused. If preferred, particle infusion can be alternated with contrast infusion, to check for stasis or backflow. Radiation dose absorbed, depends on microsphere distribution within the tumor vascularization. Equal distribution is necessary to ensure tumor cells are not spared due to ~2.5mm mean tissue penetration, with maximum penetration up to 11mm for 90Y [46] or 8.7mm for 166Ho. [47]

After treatment, for 90Y microspheres, bremsstrahlung SPECT or PET scanning may be done within 24 hours after radioembolization to evaluate the distribution. For 166Ho microspheres, quantitative SPECT or MRI can be done. Weeks after treatment, computed tomography or MRI can be done to evaluate anatomic changes. 166Ho microspheres are still visible on MRI after radioactivity has decayed, because holmium is paramagnetic. FDG positron emission tomography may also be done to evaluate changes in metabolic activity.

Adverse effects

Complications include postradioembolization syndrome (PRS), hepatic complications, biliary complications, portal hypertension and lymphopenia. Complications due to extrahepatic deposition include radiation pneumonitis, gastrointestinal ulcers and vascular injury. [48]

Postradioembolization syndrome (PRS) includes fatigue, nausea, vomiting, abdominal discomfort or pain, and cachexia, occurring in 20-70% of patients. Steroids and antiemetic agents may decrease the incidence of PRS. [49]

Liver complications include cirrhosis leading to portal hypertension, radioembolization-induced liver disease (REILD), transient elevations in liver enzymes, and fulminant liver failure. [49] REILD is characterized by jaundice, ascites, hyperbilirubinemia and hypoalbuminemia developing at least 2 weeks-4 months after SIRT, absent tumor progression or biliary obstruction. It can range from minor to fatal and is related to (over)exposure of healthy liver tissue to radiation. [49] [50]

Biliary complications include cholecystitis and biliary strictures.

History

Investigation of yttrium-90 and other radioisotopes for cancer treatment began in the 1960s. Many key concepts, such as preferential blood supply and tumor vascularity, were discovered during this time. Reports of initial use of resin particles of 90Y in humans were published in the late 1970s. In the 1980s, the safety and feasibility of resin and glass yttrium-90 microsphere therapy for liver cancer were validated in a canine model. Clinical trials of yttrium-90 applied to the liver continued throughout the late 1980s to the 1990s, establishing the safety of the therapy. More recently, larger trials and RCTs have shown safety and efficacy of 90Y therapy for the treatment of both primary and metastatic liver malignancies. [40] [51]

Development of holmium-166 microspheres started in the 1990s. The intention was to develop a microsphere with therapeutic radiation dose similar to 90Y, but with better imaging properties, so that distribution of microspheres in the liver could be assessed more precisely. In the 2000s, development progressed to animal studies. 166Ho microspheres for SIRT were first used in humans in 2009, which was first published in 2012. [52] Since then, several trials have been performed showing safety and efficacy of 166Ho SIRT, [53] and more studies are ongoing. [54]

See also

Related Research Articles

<span class="mw-page-title-main">Radiation therapy</span> Therapy using ionizing radiation, usually to treat cancer

Radiation therapy or radiotherapy is a treatment using ionizing radiation, generally provided as part of cancer therapy to either kill or control the growth of malignant cells. It is normally delivered by a linear particle accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body, and have not spread to other parts. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.

<span class="mw-page-title-main">Hepatocellular carcinoma</span> Medical condition

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis. HCC is the third leading cause of cancer-related deaths worldwide.

<span class="mw-page-title-main">Cholangiocarcinoma</span> Bile duct adenocarcinoma

Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. Light colored stool or dark urine may also occur. Other biliary tract cancers include gallbladder cancer and cancer of the ampulla of Vater.

Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.

Hepatectomy is the surgical resection of the liver. While the term is often employed for the removal of the liver from a liver transplant donor, this article will focus on partial resections of hepatic tissue and hepatoportoenterostomy.

<span class="mw-page-title-main">Neuroendocrine tumor</span> Medical condition

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung, and the rest of the body.

Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.

<span class="mw-page-title-main">Sirtex</span> Medical cancer treatment company

Sirtex Medical Limited is a medical device company, providing radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres. Sirtex was established in 1997 in Australia and currently maintains offices and manufacturing facilities in the U.S., Australia, Germany, and Singapore. Following an acquisition by China Grand Pharmaceutical and CDH Genetech, Sirtex delisted from the Australian Securities Exchange (ASX:SRX) on Monday, September 24, 2018.

<span class="mw-page-title-main">Liver cancer</span> Medical condition

Liver cancer is cancer that starts in the liver. Liver cancer can be primary or secondary. Liver metastasis is more common than that which starts in the liver. Liver cancer is increasing globally.

TheraSphere is a radiotherapy treatment for hepatocellular carcinoma (HCC) that consists of millions of microscopic, radioactive glass microspheres being infused into the arteries that feed liver tumors. These microspheres then embolize, lodging themselves in the liver's capillaries and bathing the malignancy in high levels of yttrium-90 radiation. It is currently approved as a Humanitarian Device, meaning effectiveness has not been proven, for patients as a neoadjuvant to surgery or transplantation by the U.S. Food and Drug Administration and is being used at a number of clinical centers in the United States.

Tegafur/uracil is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer. It is also called UFT or UFUR.

Hepatic arterial infusion (HAI) is a medical procedure that delivers chemotherapy directly to the liver. The procedure, mostly used in combination with systemic chemotherapy, plays a role in the treatment of liver metastases in patients with colorectal cancer (CRC). Although surgical resection remains the standard of care for these liver metastases, majority of patients have lesions that are unresectable.

In oncology, metastasectomy is the surgical removal of metastases, which are secondary cancerous growths that have spread from cancer originating in another organ in the body.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

SIR-Spheres microspheres are used to treat patients with unresectable liver cancer. These are mostly patients with hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), or metastatic neuroendocrine tumours (mNET).

Yttrium-90 is an isotope of yttrium. Yttrium-90 has found a wide range of uses in radiation therapy to treat some forms of cancer.

<span class="mw-page-title-main">Brain metastasis</span> Cancer that has metastasized (spread) to the brain from another location in the body

A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, as primary tumors that originate in the brain are less common. The most common sites of primary cancer which metastasize to the brain are lung, breast, colon, kidney, and skin cancer. Brain metastases can occur in patients months or even years after their original cancer is treated. Brain metastases have a poor prognosis for cure, but modern treatments are allowing patients to live months and sometimes years after the diagnosis.

Interventional oncology is a subspecialty field of interventional radiology that deals with the diagnosis and treatment of cancer and cancer-related problems using targeted minimally invasive procedures performed under image guidance. Interventional oncology has developed to a separate pillar of modern oncology and it employs X-ray, ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) to help guide miniaturized instruments to allow targeted and precise treatment of solid tumours located in various organs of the human body, including but not limited to the liver, kidneys, lungs, and bones. Interventional oncology treatments are routinely carried out by interventional radiologists in appropriate settings and facilities.

Radiation lobectomy is a form of radiation therapy used in interventional radiology to treat liver cancer. It is performed in patients that would be surgical candidates for resection, but cannot undergo surgery due to insufficient remaining liver tissue. It consists of injecting small radioactive beads loaded with yttrium-90 into the hepatic artery feeding the hepatic lobe in which the tumor is located. This is done with the intent of inducing growth in the contralateral hepatic lobe, not dissimilarly from portal vein embolization (PVE).

Transarterial bland embolization is a catheter-based tumor treatment of the liver. In this procedure, embolizing agents can be delivered through the tumor’s feeding artery in order to completely occlude the tumor’s blood supply. The anti-tumor effects are solely based on tumor ischemia and infarction of tumor tissue, as no chemotherapeutic agents are administered. The rationale for the use of bland embolization for hepatocellular carcinoma (HCC) and/or other hyper-vascular tumors is based on the fact that a normal liver receives a dual blood supply from the hepatic artery (25%) and the portal vein (75%). As the tumor grows, it becomes increasingly dependent on the hepatic artery for blood supply. Once a tumor nodule reaches a diameter of 2 cm or more, most of the blood supply is derived from the hepatic artery. Therefore, bland embolization and transarterial chemoembolization (TACE) consist of the selective angiographic occlusion of the tumor arterial blood supply with a variety of embolizing agents, with or without the precedence of local chemotherapy infusion. The occlusion by embolic particles results in tumor hypoxia and necrosis, without affecting the normal hepatic parenchyma.

References

  1. ↑ Cromheecke, M.; Konings, A. W.; Szabo, B. G.; Hoekstra, H. J. (November 2000). "Liver tissue tolerance for irradiation: experimental and clinical investigations". Hepato-Gastroenterology. 47 (36): 1732–1740. ISSN   0172-6390. PMID   11149044.
  2. ↑ Gates, Vanessa L; Atassi, Bassel; Lewandowski, Robert J; Ryu, Robert K; Sato, Kent T; Nemcek, Albert A; Omary, Reed; Salem, Riad (2007-02-05). "Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors". Future Oncology. 3 (1): 73–81. doi:10.2217/14796694.3.1.73. PMID   17280504.
  3. ↑ Riaz, Ahsun; Gates, Vanessa L.; Atassi, Bassel; Lewandowski, Robert J.; Mulcahy, Mary F.; Ryu, Robert K.; Sato, Kent T.; Baker, Talia; Kulik, Laura (2011). "Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization". International Journal of Radiation Oncology, Biology, Physics. 79 (1): 163–171. doi:10.1016/j.ijrobp.2009.10.062. PMID   20421150.
  4. 1 2 Salem, Riad; Lewandowski, Robert J.; Mulcahy, Mary F.; Riaz, Ahsun; Ryu, Robert K.; Ibrahim, Saad; Atassi, Bassel; Baker, Talia; Gates, Vanessa (January 2010). "Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes". Gastroenterology. 138 (1): 52–64. doi:10.1053/j.gastro.2009.09.006. ISSN   1528-0012. PMID   19766639.
  5. 1 2 Van Cutsem, E.; Cervantes, A.; Adam, R.; Sobrero, A.; Krieken, Van; H, J.; Aderka, D.; Aranda Aguilar, E.; Bardelli, A. (2016-08-01). "ESMO consensus guidelines for the management of patients with metastatic colorectal cancer". Annals of Oncology. 27 (8): 1386–1422. doi: 10.1093/annonc/mdw235 . hdl: 10400.26/14245 . ISSN   0923-7534. PMID   27380959.
  6. ↑ Smits, Maarten L. J.; Prince, Jip F.; Rosenbaum, Charlotte E. N. M.; van den Hoven, Andor F.; Nijsen, J. Frank W.; Zonnenberg, Bernard A.; Seinstra, Beatrijs A.; Lam, Marnix G. E. H.; van den Bosch, Maurice A. A. J. (2013-06-05). "Intra-arterial radioembolization of breast cancer liver metastases: a structured review". European Journal of Pharmacology. 709 (1–3): 37–42. doi:10.1016/j.ejphar.2012.11.067. ISSN   1879-0712. PMID   23545356.
  7. 1 2 Elf, Anna-Karin; Andersson, Mats; Henrikson, Olof; Jalnefjord, Oscar; Ljungberg, Maria; Svensson, Johanna; Wängberg, Bo; Johanson, Viktor (2018-02-01). "Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial". World Journal of Surgery. 42 (2): 506–513. doi:10.1007/s00268-017-4324-9. ISSN   0364-2313. PMC   5762793 . PMID   29167951.
  8. 1 2 Benson, Al B.; Geschwind, Jean-Francois; Mulcahy, Mary F.; Rilling, William; Siskin, Gary; Wiseman, Greg; Cunningham, James; Houghton, Bonny; Ross, Mason (2013). "Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study". European Journal of Cancer. 49 (15): 3122–3130. doi:10.1016/j.ejca.2013.05.012. PMID   23777743.
  9. ↑ Testa, Stefano; Bui, Nam Q.; Wang, David S.; Louie, John D.; Sze, Daniel Y.; Ganjoo, Kristen N. (10 January 2022). "Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas". Cancers. 14 (2): 324. doi: 10.3390/cancers14020324 . PMC   8774147 . PMID   35053486.
  10. ↑ Bennink, Roelof J.; Cieslak, Kasia P.; Delden, Van; M, Otto; Lienden, Van; P, Krijn; Klümpen, Heinz-Josef; Jansen, Peter L.; Gulik, Van (2014). "Monitoring of Total and Regional Liver Function after SIRT". Frontiers in Oncology. 4: 152. doi: 10.3389/fonc.2014.00152 . ISSN   2234-943X. PMC   4058818 . PMID   24982851.
  11. ↑ Fendler, Wolfgang P.; Lechner, Hanna; Todica, Andrei; Paprottka, Karolin J.; Paprottka, Philipp M.; Jakobs, Tobias F.; Michl, Marlies; Bartenstein, Peter; Lehner, Sebastian (2016-04-01). "Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients". Journal of Nuclear Medicine. 57 (4): 517–523. doi: 10.2967/jnumed.115.165050 . ISSN   0161-5505. PMID   26742710.
  12. ↑ "FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer - Full Text View - ClinicalTrials.gov" . Retrieved 2018-03-29.
  13. ↑ Sharma, Ricky. "ISRCTN - ISRCTN83867919: FOXFIRE: an open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer". www.isrctn.com. doi: 10.1186/ISRCTN83867919 . Retrieved 2018-03-29.
  14. ↑ "FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer - Full Text View - ClinicalTrials.gov" . Retrieved 2018-03-29.
  15. ↑ "SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma - Full Text View - ClinicalTrials.gov" . Retrieved 2018-03-29.
  16. ↑ "Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) - Full Text View - ClinicalTrials.gov" . Retrieved 2018-03-29.
  17. ↑ Vilgrain, Valérie; Pereira, Helena; Assenat, Eric; Guiu, Boris; Ilonca, Alina Diana; Pageaux, Georges-Philippe; Sibert, Annie; Bouattour, Mohamed; Lebtahi, Rachida (2017). "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial". The Lancet Oncology. 18 (12): 1624–1636. doi:10.1016/s1470-2045(17)30683-6. PMID   29107679.
  18. ↑ Chow, Pierce K.H.; Gandhi, Mihir; Tan, Say-Beng; Khin, Maung Win; Khasbazar, Ariunaa; Ong, Janus; Choo, Su Pin; Cheow, Peng Chung; Chotipanich, Chanisa (2018-03-02). "SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma". Journal of Clinical Oncology. 36 (19): 1913–1921. doi:10.1200/jco.2017.76.0892. ISSN   0732-183X. PMID   29498924. S2CID   3678445.
  19. ↑ Wasan, Harpreet S.; Gibbs, Peter; Sharma, Navesh K.; Taieb, Julien; Heinemann, Volker; Ricke, Jens; Peeters, Marc; Findlay, Michael; Weaver, Andrew (September 2017). "First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials". The Lancet. Oncology. 18 (9): 1159–1171. doi:10.1016/S1470-2045(17)30457-6. PMC   593813 . PMID   28781171.
  20. ↑ van Hazel, Guy A.; Heinemann, Volker; Sharma, Navesh K.; Findlay, Michael P. N.; Ricke, Jens; Peeters, Marc; Perez, David; Robinson, Bridget A.; Strickland, Andrew H. (2016-05-20). "SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer". Journal of Clinical Oncology. 34 (15): 1723–1731. doi:10.1200/JCO.2015.66.1181. hdl: 10067/1382880151162165141 . ISSN   1527-7755. PMID   26903575. S2CID   21938879.
  21. ↑ Salem, Riad; Gabr, Ahmed; Riaz, Ahsun; Mora, Ronald; Ali, Rehan; Abecassis, Michael; Hickey, Ryan; Kulik, Laura; Ganger, Daniel (2017-12-01). "Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience". Hepatology. 68 (4): 1429–1440. doi: 10.1002/hep.29691 . ISSN   1527-3350. PMID   29194711.
  22. ↑ "Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer - Full Text View - ClinicalTrials.gov" . Retrieved 2018-03-29.
  23. ↑ "Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer - Full Text View - ClinicalTrials.gov" . Retrieved 2018-03-29.
  24. ↑ "Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer - Full Text View - ClinicalTrials.gov" . Retrieved 2018-03-29.
  25. ↑ "Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer - Full Text View - ClinicalTrials.gov" . Retrieved 2018-03-29.
  26. ↑ Levi Sandri, Giovanni Battista; Ettorre, Giuseppe Maria; Giannelli, Valerio; Colasanti, Marco; Sciuto, Rosa; Pizzi, Giuseppe; Cianni, Roberto; D'Offizi, Gianpiero; Antonini, Mario (2017-11-27). "Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review". Translational Gastroenterology and Hepatology. 2 (11): 98. doi: 10.21037/tgh.2017.11.11 . PMC   5723750 . PMID   29264436.
  27. ↑ Salem, Riad; Gordon, Andrew C.; Mouli, Samdeep; Hickey, Ryan; Kallini, Joseph; Gabr, Ahmed; Mulcahy, Mary F.; Baker, Talia; Abecassis, Michael (2016). "Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma". Gastroenterology. 151 (6): 1155–1163.e2. doi:10.1053/j.gastro.2016.08.029. PMC   5124387 . PMID   27575820.
  28. ↑ Padia, Siddharth A.; Johnson, Guy E.; Horton, Kathryn J.; Ingraham, Christopher R.; Kogut, Matthew J.; Kwan, Sharon; Vaidya, Sandeep; Monsky, Wayne L.; Park, James O. (2017). "Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score–Matched Study". Journal of Vascular and Interventional Radiology. 28 (6): 777–785.e1. doi:10.1016/j.jvir.2017.02.018. PMID   28365172.
  29. ↑ Elschot, Mattijs; Vermolen, Bart J.; Lam, Marnix G. E. H.; Keizer, Bart de; Bosch, Maurice A. A. J. van den; Jong, Hugo W. A. M. de (2013-02-06). "Quantitative Comparison of PET and Bremsstrahlung SPECT for Imaging the In Vivo Yttrium-90 Microsphere Distribution after Liver Radioembolization". PLOS ONE. 8 (2): e55742. Bibcode:2013PLoSO...855742E. doi: 10.1371/journal.pone.0055742 . ISSN   1932-6203. PMC   3566032 . PMID   23405207.
  30. ↑ Smits, Maarten L. J.; Elschot, Mattijs; Sze, Daniel Y.; Kao, Yung H.; Nijsen, Johannes F. W.; Iagaru, Andre H.; de Jong, Hugo W. A. M.; van den Bosch, Maurice A. A. J.; Lam, Marnix G. E. H. (April 2015). "Radioembolization dosimetry: the road ahead". CardioVascular and Interventional Radiology. 38 (2): 261–269. doi:10.1007/s00270-014-1042-7. ISSN   1432-086X. PMID   25537310. S2CID   20959751.
  31. ↑ Smits, Maarten L. J.; Elschot, Mattijs; van den Bosch, Maurice A. A. J.; van de Maat, Gerrit H.; van het Schip, Alfred D.; Zonnenberg, Bernard A.; Seevinck, Peter R.; Verkooijen, Helena M.; Bakker, Chris J. (December 2013). "In vivo dosimetry based on SPECT and MR imaging of 166Ho-microspheres for treatment of liver malignancies". Journal of Nuclear Medicine. 54 (12): 2093–2100. doi: 10.2967/jnumed.113.119768 . ISSN   1535-5667. PMID   24136931.
  32. 1 2 3 Giammarile, Francesco; Bodei, Lisa; Chiesa, Carlo; Flux, Glenn; Forrer, Flavio; Kraeber-Bodere, Françoise; Brans, Boudewijn; Lambert, Bieke; Konijnenberg, Mark; Borson-Chazot, Françoise; Tennvall, Jan; Luster, Markus (July 2011). "EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds" (PDF). European Journal of Nuclear Medicine and Molecular Imaging. 38 (7): 1393–1406. doi:10.1007/s00259-011-1812-2. PMID   21494856. S2CID   15661029.
  33. 1 2 d’Abadie, Philippe; Hesse, Michel; Louppe, Amandine; Lhommel, Renaud; Walrand, Stephan; Jamar, Francois (29 June 2021). "Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects". Molecules. 26 (13): 3966. doi: 10.3390/molecules26133966 . PMC   8271370 . PMID   34209590.
  34. 1 2 3 4 Westcott, Mark A.; Coldwell, Douglas M.; Liu, David M.; Zikria, Joseph F. (October 2016). "The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres". Advances in Radiation Oncology. 1 (4): 351–364. doi:10.1016/j.adro.2016.08.003. PMC   5514171 . PMID   28740906.
  35. ↑ Bombardieri, Emilio; Seregni, Ettore; Evangelista, Laura; Chiesa, Carlo; Chiti, Arturo (2018). Clinical Applications of Nuclear Medicine Targeted Therapy. Cham: Springer. p. 113. doi:10.1007/978-3-319-63067-0. ISBN   9783319630663. S2CID   4423232.
  36. ↑ Vente, M. A. D.; Wondergem, M.; van der Tweel, I.; van den Bosch, M. A. A. J.; Zonnenberg, B. A.; Lam, M. G. E. H.; van het Schip, A. D.; Nijsen, J. F. W. (April 2009). "Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis". European Radiology. 19 (4): 951–959. doi: 10.1007/s00330-008-1211-7 . PMID   18989675.
  37. 1 2 3 "Information about QuiremSpheres, SIR-Spheres and TheraSphere | Selective internal radiation therapies for treating hepatocellular carcinoma | Technology appraisal guidance [TA688]". NICE . 31 March 2021. Retrieved 25 October 2021.
  38. ↑ Chu, S Y F; Ekström, L P; Firestone, R B (1999). "Yttrium-99". The Lund/LBNL Nuclear Data Search. Lund University. Retrieved 25 October 2021.
  39. ↑ Chu, S Y F; Ekström, L P; Firestone, R B (1999). "Holmium-166". The Lund/LBNL Nuclear Data Search. Lund University. Retrieved 25 October 2021.
  40. 1 2 Westcott, Mark A.; Coldwell, Douglas M.; Liu, David M.; Zikria, Joseph F. (2016). "The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres". Advances in Radiation Oncology. 1 (4): 351–364. doi:10.1016/j.adro.2016.08.003. PMC   5514171 . PMID   28740906.
  41. ↑ "QuiremSpheres". Quirem. Retrieved 25 October 2021.
  42. ↑ Kennedy, A; Nag S; Salem R; et al. (2007). "Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium". Int J Radiat Oncol Biol Phys. 68 (1): 13–23. doi:10.1016/j.ijrobp.2006.11.060. PMID   17448867.
  43. ↑ Boas, F. Edward; Bodei, Lisa; Sofocleous, Constantinos T. (September 2017). "Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes". Journal of Nuclear Medicine. 58 (Suppl 2): 104S–111S. doi: 10.2967/jnumed.116.187229 . ISSN   1535-5667. PMC   6944173 . PMID   28864605.
  44. ↑ Cremonesi, Marta; Chiesa, Carlo; Strigari, Lidia; Ferrari, Mahila; Botta, Francesca; Guerriero, Francesco; De Cicco, Concetta; Bonomo, Guido; Orsi, Franco (2014). "Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective". Frontiers in Oncology. 4: 210. doi: 10.3389/fonc.2014.00210 . PMC   4137387 . PMID   25191640.
  45. ↑ Braat, Arthur J. A. T.; Smits, Maarten L. J.; Braat, Manon N. G. J. A.; van den Hoven, Andor F.; Prince, Jip F.; de Jong, Hugo W. A. M.; van den Bosch, Maurice A. A. J.; Lam, Marnix G. E. H. (July 2015). "90Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments". Journal of Nuclear Medicine. 56 (7): 1079–1087. doi: 10.2967/jnumed.115.157446 . ISSN   1535-5667. PMID   25952741.
  46. ↑ Singh P, Anil G. Yttrium-90 radioembolization of liver tumors: what do the images tell us?. Cancer Imaging. 2014;13(4):645-57.
  47. ↑ Prince, Jip F.; Smits, Maarten L. J.; Krijger, Gerard C.; Zonnenberg, Bernard A.; van den Bosch, Maurice A. A. J.; Nijsen, Johannes F. W.; Lam, Marnix G. E. H. (December 2014). "Radiation emission from patients treated with holmium-166 radioembolization". Journal of Vascular and Interventional Radiology. 25 (12): 1956–1963.e1. doi:10.1016/j.jvir.2014.09.003. ISSN   1535-7732. PMID   25311966.
  48. ↑ Riaz, A; Lewandowski RJ; Kulik LM; et al. (2009). "Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review". Journal of Vascular and Interventional Radiology. 20 (9): 1121–1130. doi:10.1016/j.jvir.2009.05.030. PMID   19640737.
  49. 1 2 3 Riaz, Ahsun; Awais, Rafia; Salem, Riad (2014). "Side Effects of Yttrium-90 Radioembolization". Frontiers in Oncology. 4: 198. doi: 10.3389/fonc.2014.00198 . ISSN   2234-943X. PMC   4114299 . PMID   25120955.
  50. ↑ Braat, Manon N.G.J.A.; Erpecum, Karel J. van; Zonnenberg, Bernard A.; Bosch, Maurice A.J. van den; Lam, Marnix G.E.H. (2017). "Radioembolization-induced liver disease". European Journal of Gastroenterology & Hepatology. 29 (2): 144–152. doi:10.1097/meg.0000000000000772. PMID   27926660. S2CID   22379124.
  51. ↑ Atassi, B; Gates VL; Lewandowski RJ; et al. (2007). "Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors". Future Oncology. 3 (1): 73–81. doi:10.2217/14796694.3.1.73. PMID   17280504.
  52. ↑ Smits, Maarten LJ; Nijsen, Johannes FW; Bosch, Maurice AAJ van den; Lam, Marnix GEH; Vente, Maarten AD; Mali, Willem PTM; Schip, Alfred D van het; Zonnenberg, Bernard A (2012). "Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study". The Lancet Oncology. 13 (10): 1025–1034. doi:10.1016/s1470-2045(12)70334-0. PMID   22920685.
  53. ↑ Prince, Jip F.; Bosch, Maurice A. A. J. van den; Nijsen, J. F. W.; Smits, Maarten L. J.; Hoven, Andor F. van den; Nikolakopoulos, Stavros; Wessels, Frank J.; Bruijnen, Rutger C. G.; Braat, Manon (2017-09-15). "Efficacy of radioembolization with holmium-166 microspheres in salvage patients with liver metastases: a phase 2 study". Journal of Nuclear Medicine. 59 (4): 582–588. doi: 10.2967/jnumed.117.197194 . ISSN   0161-5505. PMID   28916623.
  54. ↑ "Clinical | QuiremSpheres". www.quiremspheres.com. Retrieved 2018-03-30.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.